Cleveland, OHNCT05805709Now EnrollingIRB Ready

Acute Kidney Injury Clinical Trial in Cleveland, OH

Access cutting-edge acute kidney injury treatment through this clinical trial at a research site in Cleveland. Study-provided care at no cost to qualified participants.

Sponsored by University of Pittsburgh

Quick Self-Assessment

See if you qualify for this Cleveland location

Preparing your pre-screening questions…

Expert Care in Cleveland

Access acute kidney injury specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related acute kidney injury treatment provided free

Apply for This Cleveland Location

Check if you qualify for this acute kidney injury clinical trial in Cleveland, OH

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Cleveland

    Convenient for OH residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Cleveland site if eligible
  4. 4Begin participation

About This Acute Kidney Injury Study in Cleveland

The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site.

Sponsor: University of Pittsburgh

Who Can Participate

Inclusion Criteria

Aged ≥ 18 years
Kidney Disease Improving Global Outcomes (KDIGO) Stage 2/3 AKI with evidence of persistent AKI (defined as meeting Stage 2+ AKI for 2 consecutive days with serum creatinine concentration measurements \>12 hours apart)

Exclusion Criteria

AKI due to primary glomerulonephritis, renal vasculitis, or thrombotic microangiopathy
Diagnosis of end-stage kidney disease (ESKD) at the time of admission, defined as:
Baseline estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73m2
Previous kidney transplant recipient
On chronic dialysis
Acute urinary obstruction with rapid kidney function improvement following relief of obstruction
Index hospitalization involving nephrectomy
Index hospitalization involving solid organ transplant or stem cell/bone marrow transplant
Continued dialysis dependence at time of discharge
Previous (within 6 months) or new referral to a nephrologist for care specifically for:
Previous or new diagnosis of glomerulonephritis
Primary electrolyte imbalance disorders unrelated to AKI (e.g., syndrome of inappropriate antidiuretic hormone secretion, Bartter syndrome)
Active treatment for acute interstitial nephritis
Non-kidney end-organ failure:
Class IV congestive heart failure
Decompensated cirrhosis with Model For End-Stage Liver Disease (MELD) \> 30 or those with a diagnosis of hepatorenal syndrome by the clinical teams
End-stage pulmonary disease (advanced stage chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, pulmonary hypertension)
Metastatic malignancy or malignancy requiring active treatment (chemotherapy, immunotherapy), such as multiple myeloma
Primary goal of care is palliation: life expectancy \<6 months
Vulnerable populations
Persons incarcerated
Persons institutionalized
Inability to provide informed consent a. Impaired cognition as demonstrated by the Brief Confusion Assessment Method (bCAM)
Concurrent enrollment in a separate greater than minimal risk interventional trial
Inability to participate in either in-person or remote visits a. Inability to participate as determined by the research team at time of discharge based on disposition (vs uniform decision across site about exclusion based on SNF)
Discharge to long-term acute care facility or other hospital-based location

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Cleveland?

Yes, this clinical trial (NCT05805709) has an active research site in Cleveland, OH that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Kidney Injury Treatment Options in Cleveland, OH

If you're searching for acute kidney injury treatment options in Cleveland, OH, this clinical trial (NCT05805709) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Cleveland research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute kidney injury specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Ready to Join in Cleveland?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Cleveland, OH